What the FDA labels say about taking them together
Dextroamphetamine and methylene blue
Dextroamphetamine's FDA label (Xelstrym) of December 23, 2025 names methylene blue in its contraindications section; the methylene blue label PlainMeds reads does not name dextroamphetamine. The dextroamphetamine label: “Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs, because of an increased risk of hypertensive crisis.”
Check it at the source: the dextroamphetamine FDA label on DailyMed (effective November 26, 2025, Azurity Pharmaceuticals, Inc.); the methylene blue FDA label on DailyMed (effective May 28, 2025, American Regent, Inc.).
What does the dextroamphetamine label say about methylene blue?
Xelstrym label (Noven Therapeutics, LLC, December 23, 2025), contraindicationsAnaphylactic reactions, Stevens-Johnson Syndrome, angioedema, and urticaria have been observed in postmarketing reports [see ADVERSE REACTIONS (6.2) ] taking monoamine oxidase inhibitors (MAOI), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see WARNINGS AND PRECAUTIONS (5.7) and DRUG INTERACTIONS (7.1) ] Known hypersensitivity to amphetamine products or other ingredients in XELSTRYM ( 4 ) Use with monoamine oxidase inhibitor (MAOI), or within 14 days of the last MAOI dose
Dexedrine Spansule label (Amneal Pharmaceuticals LLC, September 25, 2025), contraindicationsPatients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Drug Interactions ].
Source: FDA drug label (Xelstrym, NDA215401), Noven Therapeutics, LLC, effective December 23, 2025 (SPL set 0862f02a-72a8-41cc-8845-57cf4974bb6f), via openFDA
Source: FDA drug label (Dexedrine Spansule, NDA017078), Amneal Pharmaceuticals LLC, effective September 25, 2025 (SPL set cc717b9b-22ea-4c60-a1d4-ee38a40bce78), via openFDA
Source: FDA drug label (Zenzedi), Azurity Pharmaceuticals, Inc., effective November 26, 2025 (SPL set d6394df5-f2c9-47eb-b57e-f3e9cfd94f84), via openFDA; the full label on DailyMed
What does the methylene blue label say about dextroamphetamine?
Methylene blue's label (effective May 28, 2025) does not name dextroamphetamine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (PROVAYBLUE), NDA204630 (Provepharm Sas), as published by American Regent, Inc., effective May 28, 2025 (SPL set 4f6848e5-35ed-4046-b13c-3032b5ba3232), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dextroamphetamine | Methylene blue | |
|---|---|---|
| Labeled for | ADHD | n/a |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.373 per tablet 10 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once